T Scientific티사이언티픽

T Scientific is loss-making on a trailing basis and its shares have fallen sharply over the past year, with no recent news coverage in the data.

T Scientific runs a mobile coupon business and, after 2023 and 2024 mergers, information security and IT services. Trailing twelve-month revenue to H1 2026 was ₩34.5B, with an operating loss of about ₩0.5B and a net loss of about ₩1.1B. The share price closed at ₩1,500 on 26 October 2026, down 72.1% over one year, and the market value is about ₩23.7B.

What stands out

• Trailing revenue fell from ₩43.0B in 2024 to ₩36.4B in 2025, and the company posted a net loss of ₩1.3B in 2025 after a ₩2.2B net profit in 2024.
• Free cash flow was negative ₩1.3B on a trailing basis, while cash of ₩11.6B sat against borrowings of ₩5.7B.
• Balance sheet leverage looks modest, with liabilities at 16.1% of equity and a price-to-book ratio of 0.1 in the data.
• Recent filings include a major sales or supply contract (8 October 2026), a half-year report, and a rights offering decision in June 2026.
• Foreign ownership fell from 1.3% to 0% over the last 60 days, and the data shows no recent news headlines and no analyst ratings or forecasts.

What to watch

• Details and size of the rights offering and convertible bond price adjustment, which could dilute existing holders.
• Whether the October 2026 supply contract translates into revenue and a return to operating profit.
• Cash burn: trailing free cash flow was negative, so future filings on cash and borrowings will matter.